Symptom adapted therapy in GERD patients - SYMPATHY
Study identifier:D9612L00109
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomized, open, parallel-group, multi-national, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months maintenance phase following an initial 4-weeks acute treatment phase in subjects with symptoms thought to be GERD related
Medical condition
Gastroesophageal Reflux Disease (GERD).
Phase
Phase 4
Healthy volunteers
No
Study drug
esomeprazole, Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
Sex
All
Actual Enrollment
441
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Aug 2006
Primary Completion Date: 01 Aug 2007
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Michael Höcker
AstraZeneca Germany
